卡瑞利珠单抗治疗复发或转移性食管鳞癌的临床疗效及安全性  

Efficacy and safety of camrelizumab in the treatment of recurrent or metastatic esophageal squamous cell carcinoma

作　　者：张桂枫[1] 刘振华[1] 钟江鸣 李德育[1] 林莉[1] ZHANG Guifeng;LIU Zhenhua;ZHONG Jiangming;LI Deyu;LIN Li(Department of Medical Oncology,Shengli Clinical Medical College of Fujian Medical University,Fuzhou 350004,China)

机构地区：[1]福建医科大学省立临床医学院、福建省立医院肿瘤内科,福建福州350004

出　　处：《肿瘤基础与临床》2021年第5期374-377,共4页journal of basic and clinical oncology

基　　金：福建省自然科学基金资助项目(2019J01188);福建省立医院“创双高”火石基金资助项目(2019HSJJ05)。

摘　　要：目的探讨卡瑞利珠单抗治疗复发或转移性食管鳞癌的临床疗效及安全性。方法回顾性分析应用卡瑞利珠单抗治疗的20例一线及以上化疗失败的复发或转移性食管鳞癌患者临床资料,均应用卡瑞利珠单抗直至疾病进展或出现不可耐受的不良反应,并分析患者的近期疗效、远期疗效及不良反应。结果纳入研究的20例复发或转移性食管鳞癌患者的疾病控制率(DCR)为60.00%(12/20)。出现反应性皮肤毛细血管增生症(RCCEP)组DCR为78.57%,高于未出现RCCEP组的16.67%(P=0.018)。所有患者的中位疾病无进展生存时间(PFS)为2.00个月,中位总生存时间(OS)为6.75个月。出现RCCEP组患者PFS优于未出现RCCEP组(χ^(2)=6.487,P=0.011);2组患者OS比较差异无统计学意义(χ^(2)=0.569,P=0.451)。常见不良反应为RCCEP(70.00%)、免疫性肝炎(25.00%)、腹泻(20.00%)、甲减(20.00%)、肺炎(15.00%)、白细胞减少(10.00%)、甲亢(5.00%)、肾炎(5.00%)。结论卡瑞利珠单抗治疗复发或转移性食管鳞癌安全有效,能够有效控制疾病进展,改善患者生存,且安全性较高。Objective To investigate the clinical efficacy and safety of camrelizumab in the treatment of recurrent or metastatic esophageal squamous cell carcinoma.Methods The clinical data of 20 patients with recurrent or metastatic esophageal squamous cell carcinoma who failed to first-line standard chemotherapy and subsequent chemotherapy were analyzed retrospectively.Camrelizumab was given till disease progression or intolerable toxicity.The short-term efficacy,long-term efficacy and toxicity were analyzed.Results Of all the 20 patients,the disease control rate(DCR)was 60.00%(12/20).The DCR of the reactive cutaneous capillary endothelial proliferation(RCCEP)group(78.57%)was higher than that of the no-RCCEP group 16.67%(P=0.018).The median progression-free-survival(PFS)of all the 20 patients was 2.00 months,and the median overall survival(OS)was 6.75 months.The PFS of the RCCEP group was better than that of the no-RCCEP group(χ^(2)=6.487,P=0.011).There was no statistical difference in the OS between the two groups(χ^(2)=0.569,P=0.451).The common toxicities were RCCEP(70.00%),hepatitis(25.00%),diarrhea(20.00%),hypothyroidism(20.00%),pneumonitis(15.00%),leucopenia(10.00%),hyperthyroidism(5.00%),nephritis(5.00%).Conclusion Camrelizumab has antitumor activity in recurrent or metastatic esophageal squamous cell carcinoma,can effectively control disease progression,improve patient survival,and has high safety.

关 键 词：卡瑞利珠单抗 食管鳞癌 疗效 反应性皮肤毛细血管增生症 

分 类 号：R735.1[医药卫生—肿瘤]